Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society..
CONTEXT: Osteoporosis results from disturbances in bone formation and resorption. Recent nonhuman data suggest that the reproductive hormone kisspeptin directly stimulates osteoblast differentiation in vitro and thus could have clinical therapeutic potential. However, the effects of kisspeptin on human bone metabolism are currently unknown.
OBJECTIVE: To assess the effects of kisspeptin on human bone metabolism in vitro and in vivo.
METHODS: In vitro study: of Mono- and cocultures of human osteoblasts and osteoclasts treated with kisspeptin. Clinical study: Randomized, placebo-controlled, double-blind, 2-way crossover clinical study in 26 men investigating the effects of acute kisspeptin administration (90 minutes) on human bone metabolism, with blood sampling every 30 minutes to +90 minutes. Cells for the in vitro study were from 12 male blood donors and 8 patients undergoing hip replacement surgery. Twenty-six healthy eugonadal men (age 26.8 ± 5.8 years) were included in the clinical study. The intervention was Kisspeptin (vs placebo) administration. The main outcome measures were changes in bone parameters and turnover markers.
RESULTS: Incubation with kisspeptin in vitro increased alkaline phosphatase levels in human bone marrow mesenchymal stem cells by 41.1% (P = .0022), and robustly inhibited osteoclastic resorptive activity by up to 53.4% (P < .0001), in a dose-dependent manner. Kisspeptin administration to healthy men increased osteoblast activity, as evidenced by a 20.3% maximal increase in total osteocalcin (P = .021) and 24.3% maximal increase in carboxylated osteocalcin levels (P = .014).
CONCLUSION: Collectively, these data provide the first human evidence that kisspeptin promotes osteogenic differentiation of osteoblast progenitors and inhibits bone resorption in vitro. Furthermore, kisspeptin acutely increases the bone formation marker osteocalcin but not resorption markers in healthy men, independent of downstream sex steroid levels. Kisspeptin could therefore have clinical therapeutic application in the treatment of osteoporosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 107(2022), 6 vom: 17. Mai, Seite 1529-1540 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Comninos, Alexander N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
104982-03-8 |
|---|
| Anmerkungen: |
Date Completed 19.05.2022 Date Revised 16.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgac117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337758255 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337758255 | ||
| 003 | DE-627 | ||
| 005 | 20231225235135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgac117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337758255 | ||
| 035 | |a (NLM)35244717 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Comninos, Alexander N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2022 | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a CONTEXT: Osteoporosis results from disturbances in bone formation and resorption. Recent nonhuman data suggest that the reproductive hormone kisspeptin directly stimulates osteoblast differentiation in vitro and thus could have clinical therapeutic potential. However, the effects of kisspeptin on human bone metabolism are currently unknown | ||
| 520 | |a OBJECTIVE: To assess the effects of kisspeptin on human bone metabolism in vitro and in vivo | ||
| 520 | |a METHODS: In vitro study: of Mono- and cocultures of human osteoblasts and osteoclasts treated with kisspeptin. Clinical study: Randomized, placebo-controlled, double-blind, 2-way crossover clinical study in 26 men investigating the effects of acute kisspeptin administration (90 minutes) on human bone metabolism, with blood sampling every 30 minutes to +90 minutes. Cells for the in vitro study were from 12 male blood donors and 8 patients undergoing hip replacement surgery. Twenty-six healthy eugonadal men (age 26.8 ± 5.8 years) were included in the clinical study. The intervention was Kisspeptin (vs placebo) administration. The main outcome measures were changes in bone parameters and turnover markers | ||
| 520 | |a RESULTS: Incubation with kisspeptin in vitro increased alkaline phosphatase levels in human bone marrow mesenchymal stem cells by 41.1% (P = .0022), and robustly inhibited osteoclastic resorptive activity by up to 53.4% (P < .0001), in a dose-dependent manner. Kisspeptin administration to healthy men increased osteoblast activity, as evidenced by a 20.3% maximal increase in total osteocalcin (P = .021) and 24.3% maximal increase in carboxylated osteocalcin levels (P = .014) | ||
| 520 | |a CONCLUSION: Collectively, these data provide the first human evidence that kisspeptin promotes osteogenic differentiation of osteoblast progenitors and inhibits bone resorption in vitro. Furthermore, kisspeptin acutely increases the bone formation marker osteocalcin but not resorption markers in healthy men, independent of downstream sex steroid levels. Kisspeptin could therefore have clinical therapeutic application in the treatment of osteoporosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a bone metabolism | |
| 650 | 4 | |a kisspeptin | |
| 650 | 4 | |a osteoporosis | |
| 650 | 4 | |a reproduction | |
| 650 | 7 | |a Kisspeptins |2 NLM | |
| 650 | 7 | |a Osteocalcin |2 NLM | |
| 650 | 7 | |a 104982-03-8 |2 NLM | |
| 700 | 1 | |a Hansen, Morten S |e verfasserin |4 aut | |
| 700 | 1 | |a Courtney, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhury, Sirazum |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Edouard G |e verfasserin |4 aut | |
| 700 | 1 | |a Phylactou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Busbridge, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Khir, Muaza |e verfasserin |4 aut | |
| 700 | 1 | |a Thaventhiran, Thilipan |e verfasserin |4 aut | |
| 700 | 1 | |a Bech, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Tricia |e verfasserin |4 aut | |
| 700 | 1 | |a Abbara, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Frost, Morten |e verfasserin |4 aut | |
| 700 | 1 | |a Dhillo, Waljit S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 107(2022), 6 vom: 17. Mai, Seite 1529-1540 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2022 |g number:6 |g day:17 |g month:05 |g pages:1529-1540 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgac117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2022 |e 6 |b 17 |c 05 |h 1529-1540 | ||